Zacks Investment Research on MSN3d
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
A recent Vanderbilt study has found a cure for sickle cell disease, a blood disorder where the body creates mutated red blood ...
The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.
NY resident Sebastien Beauzile was treated with a pioneering new gene therapy approach called Lyfgenia, curing his sickle ...
The Punch on MSN3d
Gene therapy delivers alternative sickle cell cure in USSebastien Beauzile from Laurelton, Long Island, has become the first person in New York State to be cured of sickle cell ...
Sebastien Beauzile is the first person in New York to be cured of sickle cell anemia due to a genetic treatment called Lyfgenia.
CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...
Aaron Scott, of Fayetteville, is the first in North Carolina to receive a new FDA-approved therapy which uses the patient's own cells to relieve the pain of sickle cell disease.
The approval of Vertex and partner CRISPR Therapeutics CRSP one-shot gene therapy Casgevy for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback